

**As Introduced**

**125th General Assembly  
Regular Session  
2003-2004**

**H. B. No. 292**

**Representative Oelslager**

---

**A BILL**

To amend sections 1701.76 and 1701.82 and to enact 1  
sections 2307.91 to 2307.97 of the Revised Code to 2  
establish minimum medical requirements for filing 3  
certain asbestos claims and to establish 4  
limitations on successor asbestos-related 5  
liabilities relating to corporations. 6

**BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF OHIO:**

**Section 1.** That sections 1701.76 and 1701.82 be amended and 7  
sections 2307.91, 2307.92, 2307.93, 2307.94, 2307.95, 2307.96, and 8  
2307.97 of the Revised Code be enacted to read as follows: 9

**Sec. 1701.76.** (A)(1) Provided the provisions of Chapter 1704. 10  
of the Revised Code do not prevent the transaction from being 11  
effected, a lease, sale, exchange, transfer, or other disposition 12  
of all, or substantially all, of the assets, with or without the 13  
good will, of a corporation, if not made in the usual and regular 14  
course of its business, may be made upon ~~such~~ the terms and 15  
conditions and for ~~such~~ the consideration, ~~which~~ that may consist, 16  
in whole or in part, of money or other property of any 17  
description, including shares or other securities or promissory 18  
obligations of any other corporation, domestic or foreign, ~~as~~ that 19  
may be authorized as follows: 20

(a) By the directors, either before or after authorization by the shareholders as required in this section; and

(b) At a meeting of the shareholders held for ~~such~~ that purpose, by the affirmative vote of the holders of shares entitling them to exercise two-thirds of the voting power of the corporation on ~~such~~ the proposal, or, if the articles so provide or permit, by the affirmative vote of a greater or lesser proportion, but not less than a majority, of ~~such~~ the voting power, and by ~~such~~ the affirmative vote of the holders of shares of any particular class ~~as~~ that is required by the articles.

(2) At the shareholder meeting described in division (A)(1)(b) of this section or at any subsequent shareholder meeting, shareholders, by the same vote that is required to authorize the lease, sale, exchange, transfer, or other disposition of all, or substantially all, of the assets, with or without the good will, of the corporation, may grant authority to the directors to establish or amend any of the terms and conditions of the transaction, except that the shareholders shall not authorize the directors to do any of the following:

(a) Alter or change the amount or kind of shares, securities, money, property, or rights to be received in exchange for the assets;

(b) Alter or change to any material extent the amount or kind of liabilities to be assumed in exchange for the assets;

(c) Alter or change any other terms and conditions of the transaction if any of the alterations or changes, alone or in the aggregate, would materially adversely affect the shareholders or the corporation.

(3) Notice of the meeting of the shareholders described in division (A)(1)(b) of this section shall be given to all shareholders whether or not entitled to vote at the meeting and

shall be accompanied by a copy or summary of the terms of the 52  
transaction. 53

(B) The corporation by its directors may abandon ~~such the~~ 54  
transaction under this section, subject to the contract rights of 55  
other persons, if the power of abandonment is conferred upon the 56  
directors either by the terms of the transaction or by the same 57  
vote of shareholders and at the same meeting of shareholders as 58  
that referred to in division (A)(1)(b) of this section or at any 59  
subsequent meeting. 60

(C) Dissenting holders of shares of any class, whether or not 61  
entitled to vote, shall be entitled to relief under section 62  
1701.85 of the Revised Code. 63

(D) An action to set aside a conveyance by a corporation, on 64  
the ground that any section of the Revised Code applicable to the 65  
lease, sale, exchange, transfer, or other disposition of all, or 66  
substantially all, of the assets of ~~such that~~ corporation has not 67  
been complied with, shall be brought within ninety days after ~~such~~ 68  
that transaction, or ~~such the~~ action shall be forever barred. 69

(E) If a resolution of dissolution is adopted pursuant to 70  
section 1701.86 of the Revised Code, the directors may dispose of 71  
all, or substantially all, of the corporation's assets without the 72  
necessity of a shareholders' authorization under this section. 73

(F) The terms and conditions of any transaction under this 74  
section shall be subject to the limitations specified in section 75  
2307.96 of the Revised Code. 76

**Sec. 1701.82.** (A) When a merger or consolidation becomes 77  
effective, all of the following apply: 78

(1) The separate existence of each constituent entity other 79  
than the surviving entity in a merger shall cease, except that 80  
whenever a conveyance, assignment, transfer, deed, or other 81

instrument or act is necessary to vest property or rights in the 82  
surviving or new entity, the officers, general partners, or other 83  
authorized representatives of the respective constituent entities 84  
shall execute, acknowledge, and deliver ~~such~~ those instruments and 85  
do ~~such~~ those acts. For these purposes, the existence of the 86  
constituent entities and the authority of their respective 87  
officers, directors, general partners, or other authorized 88  
representatives is continued notwithstanding the merger or 89  
consolidation. 90

(2) In the case of a consolidation, the new entity exists 91  
when the consolidation becomes effective and, if it is a domestic 92  
corporation, the articles contained in or provided for in the 93  
agreement of consolidation shall be its original articles. In the 94  
case of a merger in which the surviving entity is a domestic 95  
corporation, the articles of the domestic surviving corporation in 96  
effect immediately prior to the time the merger becomes effective 97  
shall continue as its articles after the merger except as 98  
otherwise provided in the agreement of merger. 99

(3) The surviving or new entity possesses all assets and 100  
property of every description, and every interest in the assets 101  
and property, wherever located, and the rights, privileges, 102  
immunities, powers, franchises, and authority, of a public as well 103  
as of a private nature, of each constituent entity, and, subject 104  
to the limitations specified in section 2307.96 of the Revised 105  
Code, all obligations belonging to or due to each constituent 106  
entity, all of which are vested in the surviving or new entity 107  
without further act or deed. Title to any real estate or any 108  
interest in the real estate vested in any constituent entity shall 109  
not revert or in any way be impaired by reason of such merger or 110  
consolidation. 111

(4) The Subject to the limitations specified in section 112  
2307.96 of the Revised Code, the surviving or new entity is liable 113

for all the obligations of each constituent entity, including 114  
liability to dissenting shareholders. Any claim existing or any 115  
action or proceeding pending by or against any constituent entity 116  
may be prosecuted to judgment, with right of appeal, as if the 117  
merger or consolidation had not taken place, or the surviving or 118  
new entity may be substituted in its place. 119

(5) ~~All~~ Subject to the limitations specified in section 120  
2307.96 of the Revised Code, all the rights of creditors of each 121  
constituent entity are preserved unimpaired, and all liens upon 122  
the property of any constituent entity are preserved unimpaired, 123  
on only the property affected by ~~such~~ those liens immediately 124  
prior to the effective date of the merger or consolidation. If a 125  
general partner of a constituent partnership is not a general 126  
partner of the entity surviving or the new entity resulting from 127  
the merger or consolidation, then the former general partner shall 128  
have no liability for any obligation incurred after the merger or 129  
consolidation except to the extent that a former creditor of the 130  
constituent partnership in which the former general partner was a 131  
partner extends credit to the surviving or new entity reasonably 132  
believing that the former general partner continued as a general 133  
partner of the surviving or new entity. 134

(B) If a general partner of a constituent partnership is not 135  
a general partner of the entity surviving or the new entity 136  
resulting from the merger or consolidation, the provisions of 137  
division (B) of section 1782.434 of the Revised Code shall apply. 138

(C) In the case of a merger of a domestic constituent 139  
corporation into a foreign surviving corporation, limited 140  
liability company, or limited partnership that is not licensed or 141  
registered to transact business in this state or in the case of a 142  
consolidation of a domestic constituent corporation into a new 143  
foreign corporation, limited liability company, or limited 144  
partnership, if the surviving or new entity intends to transact 145

business in this state and the certificate of merger or 146  
consolidation is accompanied by the information described in 147  
division (B)(4) of section 1701.81 of the Revised Code, then, on 148  
the effective date of the merger or consolidation, the surviving 149  
or new entity shall be considered to have complied with the 150  
requirements for procuring a license or for registering to 151  
transact business in this state as a foreign corporation, limited 152  
liability company, or limited partnership, as the case may be. In 153  
such a case, a copy of the certificate of merger or consolidation 154  
certified by the secretary of state constitutes the license 155  
certificate prescribed by the laws of this state for a foreign 156  
corporation transacting business in this state or the application 157  
for registration prescribed for a foreign limited partnership or 158  
limited liability company. 159

(D) Any action to set aside any merger or consolidation on 160  
the ground that any section of the Revised Code applicable to the 161  
merger or consolidation has not been complied with shall be 162  
brought within ninety days after the effective date of ~~such~~ that 163  
merger or consolidation or be forever barred. 164

(E) As used in this section, "corporation" or "entity" 165  
applies to both domestic and foreign corporations and entities 166  
where the context so permits. In the case of a foreign constituent 167  
entity or a foreign new entity, this section is subject to the 168  
laws of the state under the laws of which the entity exists or in 169  
which it has property. 170

Sec. 2307.91. As used in sections 2307.91 to 2307.95 of the 171  
Revised Code: 172

(A) "AMA guides to the evaluation of permanent impairment" 173  
means the American medical association's guides to the evaluation 174  
of permanent impairment (fifth edition 2000) as may be modified by 175  
the American medical association. 176

(B) "Asbestos" means chrysotile, amosite, crocidolite, tremolite asbestos, anthophyllite asbestos, actinolite asbestos, and any of these minerals that have been chemically treated or altered. 177  
178  
179  
180

(C) "Asbestos claim" means any claim for damages, losses, indemnification, contribution, or other relief arising out of, based on, or in any way related to asbestos. "Asbestos claim" includes a claim made by or on behalf of any person who has been exposed to asbestos, or any representative, spouse, parent, child, or other relative of that person, for injury, including mental or emotional injury, death, or loss to person, risk of disease or other injury, costs of medical monitoring or surveillance, or any other effects on the person's health that are caused by the person's exposure to asbestos. 181  
182  
183  
184  
185  
186  
187  
188  
189  
190

(D) "Asbestosis" means bilateral diffuse interstitial fibrosis of the lungs caused by inhalation of asbestos fibers. 191  
192

(E) "Board-certified internist" means a medical doctor who is currently certified by the American board of internal medicine. 193  
194

(F) "Board-certified oncologist" means a medical doctor who is currently certified by the American board of internal medicine in the subspecialty of medical oncology. 195  
196  
197

(G) "Board-certified pathologist" means a medical doctor who is currently certified by the American board of pathology. 198  
199

(H) "Board-certified pulmonary specialist" means a medical doctor who is currently certified by the American board of internal medicine in the subspecialty of pulmonary medicine. 200  
201  
202

(I) "Certified B-reader" means an individual qualified as a "final" or "B-reader" as defined in 42 C.F.R. section 37.51(b), as amended. 203  
204  
205

(J) "Civil action" means all suits or claims of a civil 206

nature in state or federal court, whether cognizable as cases at 207  
law or in equity or admiralty. The term "civil action" does not 208  
include an action relating to any workers' compensation law. 209

(K) "Exposed person" means any person whose exposure to 210  
asbestos or to asbestos-containing products is the basis for an 211  
asbestos claim. 212

(L) "Exposure years" means the following: 213

(1) Each single year of exposure prior to 1972 will be 214  
counted as one year. 215

(2) Each single year of exposure from 1972 through 1979 will 216  
be counted as one-half year. 217

(3) Exposure after 1979 will not be counted, except that each 218  
year from 1972 forward for which the plaintiff can establish 219  
exposure exceeding the occupational safety and health 220  
administration (OSHA) limit for eight-hour time-weighted average 221  
airborne concentration for a substantial portion of the year will 222  
count as one year. 223

(M) "FEV1" means forced expiratory volume in the first 224  
second, which is the maximal volume of air expelled in one second 225  
during performance of simple spirometric tests. 226

(N) "FVC" means forced vital capacity that is maximal volume 227  
of air expired with maximum effort from a position of full 228  
inspiration. 229

(O) "ILO scale" means the system for the classification of 230  
chest x-rays set forth in the international labour office's 231  
guidelines for the use of ILO international classification of 232  
radiographs of pneumoconioses (1980), as amended. 233

(P) "Lung cancer" means a malignant tumor in which the 234  
primary site of origin of the cancer is inside the lungs, but that 235  
term does not include an asbestos claim based upon mesothelioma. 236

(O) "Mesothelioma" means a malignant tumor with a primary site of origin in the pleura or the peritoneum, which has been diagnosed by a board-certified pathologist, using standardized and accepted criteria of microscopic morphology and appropriate staining techniques. 237  
238  
239  
240  
241

(R) "Nonmalignant condition" means a condition that is caused or may be caused by asbestos other than a diagnosed cancer. 242  
243

(S) "Nonsmoker" means the exposed person has not smoked cigarettes or used any other tobacco products within the last fifteen years. 244  
245  
246

(T) "Pathological evidence of asbestosis" means a statement by a board-certified pathologist that more than one representative section of lung tissue uninvolved with any other disease process demonstrates a pattern of peribronchiolar or parenchymal scarring in the presence of characteristic asbestos bodies and that there is no other more likely explanation for the presence of the fibrosis. 247  
248  
249  
250  
251  
252  
253

(U) "Physical impairment" means a nonmalignant condition that meets the minimum requirements of division (B) of section 2307.92 of the Revised Code, lung cancer that meets the minimum requirements of division (C) of section 2307.92 of the Revised Code, or cancer of the colon, rectum, larynx, pharynx, esophagus, or stomach that meets the minimum requirements of division (D) of section 2307.92 of the Revised Code. 254  
255  
256  
257  
258  
259  
260

(V) "Predicted lower limit of normal" means the fifth percentile of healthy populations based on age, height, and gender, as referenced in the AMA guides to the evaluation of permanent impairment. 261  
262  
263  
264

(W) "Qualified physician" means a medical doctor who is providing a diagnosis for purposes of constituting prima-facie evidence of an exposed person's physical impairment that meets the 265  
266  
267

<u>requirements of section 2307.92 of the Revised Code and who meets</u>	268
<u>the following requirements:</u>	269
<u>(1) The medical doctor is a board-certified internist,</u>	270
<u>pulmonary specialist, oncologist, or pathologist.</u>	271
<u>(2) The medical doctor is actually treating or has treated</u>	272
<u>the exposed person and has or had a doctor-patient relationship</u>	273
<u>with the person.</u>	274
<u>(3) The medical doctor spends not more than ten per cent of</u>	275
<u>the medical doctor's professional practice time in providing</u>	276
<u>consulting or expert services in connection with actual or</u>	277
<u>potential civil actions, and the medical doctor's medical group,</u>	278
<u>professional corporation, clinic, or other affiliated group earns</u>	279
<u>not more than twenty per cent of its revenues from providing those</u>	280
<u>services.</u>	281
<u>(4) The medical doctor is currently licensed to practice and</u>	282
<u>actively practices in the state where the plaintiff's civil action</u>	283
<u>was filed.</u>	284
<u>(5) The medical doctor receives or received payment for the</u>	285
<u>treatment of the exposed person from that person's HMO or other</u>	286
<u>medical provider.</u>	287
<u>(X) "Radiological evidence of asbestosis" means a chest x-ray</u>	288
<u>showing small, irregular opacities (s, t) graded by a certified</u>	289
<u>B-reader as at least 1/1 on the ILO scale.</u>	290
<u>(Y) "Radiological evidence of diffuse pleural thickening"</u>	291
<u>means a chest x-ray showing bilateral pleural thickening graded by</u>	292
<u>a certified B-reader as at least B2 on the ILO scale and blunting</u>	293
<u>of at least one costophrenic angle.</u>	294
<u>(Z) "Smoker" means a person who has smoked cigarettes or</u>	295
<u>other tobacco products within the last fifteen years.</u>	296
<u>(AA) "Spirometry" means the measurement of volume of air</u>	297

inhaled or exhaled by the lung. 298

(BB) "Substantial contributing factor" means all of the 299  
following: 300

(1) Exposure to asbestos is the predominate cause of the 301  
physical impairment alleged in the asbestos claim. 302

(2) The exposure to asbestos took place on a regular basis 303  
over an extended period of time and in close proximity to the 304  
exposed person. 305

(3) A qualified physician has determined with a reasonable 306  
degree of medical certainty that the physical impairment of the 307  
exposed person would not have occurred but for the asbestos 308  
exposures. 309

(CC) "Veterans' benefit program" means any program for 310  
benefits in connection with military service administered by the 311  
veterans' administration under title 38 of the United States Code. 312

(DD) "Workers' compensation law" means Chapters 4121., 4123., 313  
4127., and 4131. of the Revised Code. 314

**Sec. 2307.92. (A) Physical impairment of the exposed person,** 315  
**to which the person's exposure to asbestos is a substantial** 316  
**contributing factor, shall be an essential element of an asbestos** 317  
**claim.** 318

(B) No person shall bring or maintain a civil action alleging 319  
an asbestos claim based on a nonmalignant condition in the absence 320  
of a prima-facie showing that the exposed person has a physical 321  
impairment, that the physical impairment is a result of a medical 322  
condition, and that the person's exposure to asbestos is a 323  
substantial contributing factor to the medical condition. That 324  
prima-facie showing shall include all of the following minimum 325  
requirements: 326

(1) Evidence verifying that a qualified physician has taken a detailed occupational and exposure history of the exposed person from the exposed person or, if that person is deceased, from the person who is most knowledgeable about the exposures that form the basis of the asbestos claim for a nonmalignant condition, including all of the following:

(a) All of the exposed person's principal places of employment and exposures to airborne contaminants;

(b) Whether each place of employment involved exposures to airborne contaminants, including, but not limited to, asbestos fibers or other disease causing dusts, that can cause pulmonary impairment and, if that type of exposure is involved, the nature, duration, and level of the exposure.

(2) Evidence verifying that a qualified physician has taken a detailed medical and smoking history of the exposed person, including a thorough review of the exposed person's past and present medical problems and the most probable causes of those medical problems;

(3) A diagnosis by a qualified physician, based on a medical examination and pulmonary function testing of the exposed person, that all of the following apply to the exposed person:

(a) The exposed person has a permanent respiratory impairment rating of at least class 2 as defined by and evaluated pursuant to the AMA guides to the evaluation of permanent impairment.

(b) The exposed person has asbestosis or diffuse pleural thickening, based at a minimum on radiological or pathological evidence of asbestosis or radiological evidence of diffuse pleural thickening.

(c) The asbestosis or diffuse pleural thickening described in division (B)(3)(b) of this section, rather than solely chronic

obstructive pulmonary disease, is a substantial contributing 357  
factor to the exposed person's physical impairment, based at a 358  
minimum on a determination that the exposed person has either of 359  
the following: 360

(i) A forced vital capacity below the predicted lower limit 361  
of normal and a ratio of FEV1 to FVC that is equal to or greater 362  
than the predicted lower limit of normal; 363

(ii) A chest x-ray showing small, irregular opacities (s, t) 364  
graded by a certified B-reader at least 2/1 on the ILO scale. 365

(C) No person shall bring or maintain a civil action alleging 366  
an asbestos claim based upon lung cancer in the absence of a 367  
prima-facie showing of all of the following minimum requirements: 368

(1) A diagnosis by a board-certified pathologist, 369  
board-certified pulmonary specialist, or board-certified 370  
oncologist that the exposed person has primary lung cancer and 371  
that exposure to asbestos is a substantial contributing factor to 372  
that cancer; 373

(2) Evidence that is sufficient to demonstrate that at least 374  
ten years have elapsed between the date of the exposed person's 375  
first exposure to asbestos and the date of diagnosis of the 376  
exposed person's primary lung cancer; 377

(3) Either of the following: 378

(a) In the case of an exposed person who is a nonsmoker, 379  
either of the following requirements: 380

(i) Radiological or pathological evidence of asbestosis or 381  
radiological evidence of diffuse pleural thickening; 382

(ii) Evidence of the exposed person's occupational exposure 383  
to asbestos for any of the applicable minimum exposure periods in 384  
the occupations as specified in divisions (D)(3)(b)(i), (ii), and 385  
(iii) of this section. 386

(b) In the case of an exposed person who is a smoker, both of 387  
the requirements specified in divisions (C)(3)(a)(i) and (ii) of 388  
this section. 389

(D) No person shall bring or maintain a civil action alleging 390  
an asbestos claim based upon cancer of the colon, rectum, larynx, 391  
pharynx, esophagus, or stomach, in the absence of a prima-facie 392  
showing of all of the following minimum requirements: 393

(1) A diagnosis by a board-certified pathologist, 394  
board-certified pulmonary specialist, or board-certified 395  
oncologist, whichever is appropriate for the type of cancer 396  
claimed, that the exposed person has primary cancer of the colon, 397  
rectum, larynx, pharynx, esophagus, or stomach and that exposure 398  
to asbestos was a substantial contributing factor to that 399  
particular cancer; 400

(2) Evidence that is sufficient to demonstrate that at least 401  
ten years have elapsed between the date of the exposed person's 402  
first exposure to asbestos and the date of diagnosis of the 403  
exposed person's particular cancer; 404

(3) Either of the following requirements: 405

(a) Radiological or pathological evidence of asbestosis or 406  
radiological evidence of diffuse pleural thickening; 407

(b) Evidence of the exposed person's occupational exposure to 408  
asbestos for any of the following applicable minimum exposure 409  
periods in the specified occupations: 410

(i) Five exposure years for insulators, shipyard workers, 411  
workers in manufacturing plants handling raw asbestos, 412  
boilermakers, shipfitters, steamfitters, or other trades 413  
performing similar functions; 414

(ii) Ten exposure years for utility and power house workers, 415  
secondary manufacturing workers, or other trades performing 416

similar functions; 417

(iii) Fifteen exposure years for general construction, 418  
maintenance workers, chemical and refinery workers, marine engine 419  
room personnel and other personnel on vessels, stationary 420  
engineers and firefighters, railroad engine repair workers, or 421  
other trades performing similar functions. 422

(E) No prima-facie showing is required in a civil action 423  
alleging an asbestos claim based upon mesothelioma. 424

(F) Evidence relating to physical impairment under this 425  
section, including pulmonary function testing and diffusing 426  
studies, shall comply with the technical recommendations for 427  
examinations, testing procedures, quality assurance, quality 428  
control, and equipment incorporated in the AMA guides to the 429  
evaluation of permanent impairment and reported as set forth in 20 430  
C.F.R. Pt. 404, Subpt. P, App. 1, Part A, Sec. 3.00 E. and F., and 431  
the interpretive standards set forth in the official statement of 432  
the American thoracic society entitled "lung function testing: 433  
selection of reference values and interpretive strategies" as 434  
published in American review of respiratory disease, 435  
1991:144:1202-1218. 436

(G) All of the following apply to the presentation of 437  
prima-facie evidence that meets the requirements of division (B), 438  
(C), or (D) of this section: 439

(1) It does not result in any presumption at trial that the 440  
exposed person has a physical impairment that is caused by an 441  
asbestos-related condition. 442

(2) It is not conclusive as to the liability of any defendant 443  
in the case. 444

(3) It is not admissible at trial. 445

**Sec. 2307.93.** The plaintiff in any civil action who alleges 446

an asbestos claim shall file together with the complaint or other 447  
initial pleading a written report and supporting test results 448  
constituting prima-facie evidence of the exposed person's physical 449  
impairment that meets the minimum requirements of division (B), 450  
(C), or (D) of section 2307.92 of the Revised Code, whichever is 451  
applicable. With respect to any asbestos claim that is pending on 452  
the effective date of this section, the plaintiff shall file the 453  
written report and supporting test results described in this 454  
section sixty days following the effective date of this section or 455  
thirty days prior to trial, whichever is earlier. The defendant in 456  
the case shall be afforded a reasonable opportunity to challenge 457  
the adequacy of the proffered prima-facie evidence of the physical 458  
impairment. The court shall dismiss the plaintiff's claim without 459  
prejudice upon a finding of failure to make the prima-facie 460  
showing required by division (B), (C), or (D) of section 2307.92 461  
of the Revised Code. 462

**Sec. 2307.94.** (A) Notwithstanding any other provision of the 463  
Revised Code, with respect to any asbestos claim based upon a 464  
nonmalignant condition that is not barred as of the effective date 465  
of this section, the period of limitations shall not begin to run 466  
until the exposed person discovers, or through the exercise of 467  
reasonable diligence should have discovered, that the person has a 468  
physical impairment due to a nonmalignant condition. 469

(B) An asbestos claim that arises out of a nonmalignant 470  
condition shall be a distinct cause of action from an asbestos 471  
claim relating to the same exposed person that arises out of 472  
asbestos-related cancer. No damages shall be awarded for fear or 473  
risk of cancer in any civil action asserting only an asbestos 474  
claim for a nonmalignant condition. 475

(C) No settlement of an asbestos claim for a nonmalignant 476

condition that is concluded after the effective date of this 477  
section shall require, as a condition of settlement, the release 478  
of any future claim for asbestos-related cancer. 479

Sec. 2307.95. Sections 2307.91 to 2307.95 of the Revised Code 480  
shall not affect the scope or operation of any workers' 481  
compensation law or veterans' benefit program or the exclusive 482  
remedy of subrogation under the provisions of that law or program 483  
and shall not authorize any lawsuit that is barred by any 484  
provision of any workers' compensation law. 485

Sec. 2307.96. (A) As used in this section and section 2307.97 486  
of the Revised Code: 487

(1) "Asbestos" has the same meaning as in section 2307.91 of 488  
the Revised Code. 489

(2) "Asbestos claim" means any claim for damages, losses, 490  
indemnification, contribution, or other relief arising out of, 491  
based on, or in any way related to asbestos. "Asbestos claim" 492  
includes any of the following: 493

(a) A claim made by or on behalf of any person who has been 494  
exposed to asbestos, or any representative, spouse, parent, child, 495  
or other relative of that person, for injury, including mental or 496  
emotional injury, death, or loss to person, risk of disease or 497  
other injury, costs of medical monitoring or surveillance, or any 498  
other effects on the person's health that are caused by the 499  
person's exposure to asbestos; 500

(b) A claim for damage or loss to property that is caused by 501  
the installation, presence, or removal of asbestos. 502

(3) "Successor" means a domestic corporation or a subsidiary 503  
of a domestic corporation that acquired any assets of or the stock 504  
of a foreign business corporation, if all of the following apply: 505

<u>(a) The transaction occurred on or before July 29, 1977.</u>	506
<u>(b) The purchasing domestic corporation paid less than five million dollars for the acquisition.</u>	507 508
<u>(c) The principal place of business of the foreign corporation was located outside the state of Ohio.</u>	509 510
<u>(4)(a) "Successor asbestos-related liabilities," in relation to an asset purchase or a stock purchase by a successor means any liabilities, whether known or unknown, asserted or unasserted, absolute or contingent, accrued or unaccrued, liquidated or unliquidated, or due or to become due, if the liabilities are related in any way to asbestos claims and are assumed or incurred by a successor as a result of or in connection with the asset purchase or stock purchase, merger, or consolidation, or the agreement of the asset purchase or stock purchase.</u>	511 512 513 514 515 516 517 518 519
<u>(b) "Successor asbestos-related liabilities" includes any liabilities described in division (A)(4)(a) of this section that, after the effective date of the asset purchase or stock purchase, are paid, otherwise discharged, committed to be paid, or committed to be otherwise discharged by or on behalf of the successor, or by or on behalf of a transferor, in connection with any judgment, settlement, or other discharge of those liabilities in this state or another jurisdiction.</u>	520 521 522 523 524 525 526 527
<u>(5) "Transferor" means a foreign corporation or its shareholders from which successor asbestos-related liabilities are assumed or incurred by the successor.</u>	528 529 530
<u>(B)(1) Except as otherwise provided in division (B)(2) of this section, the cumulative successor asbestos-related liabilities of a successor shall be limited to the fair market value of the acquired assets or stock as determined on the effective date of the asset purchase or stock purchase, merger, or consolidation.</u>	531 532 533 534 535 536

(2) If a transferor had assumed or incurred successor 537  
asbestos-related liabilities in connection with a prior asset 538  
purchase, stock purchase, merger, or consolidation involving a 539  
prior transferor, the successor asbestos-related liabilities of 540  
the successor described in division (B)(1) of this section shall 541  
be limited to the fair market value of the previously acquired 542  
assets or stock as determined on the effective date of the prior 543  
asset purchase, stock purchase, merger, or consolidation. 544

(3) The successor described in division (B)(1) or (2) of this 545  
section shall have no responsibility for any successor 546  
asbestos-related liabilities in excess of the limitation of those 547  
liabilities as described in the applicable division. 548

(C)(1) Except as otherwise provided in division (C)(2) of 549  
this section, the assets of a successor shall be exempt from 550  
restraint, attachment, or execution on any judgment entered in 551  
this state or another jurisdiction related to any claim for 552  
successor asbestos-related liabilities if the cumulative amounts 553  
of those liabilities that, after the effective date of the asset 554  
purchase or stock purchase that is covered by division (B) of this 555  
section, are paid or committed to be paid by or on behalf of the 556  
successor, or by or on behalf of the transferor, in connection 557  
with any judgment, settlement, or other discharge of claims of 558  
asbestos-related liabilities exceed the fair market value of the 559  
assets or stock as determined on the effective date of the asset 560  
purchase or stock purchase, merger, or consolidation. 561

(2) If a transferor had assumed or incurred successor 562  
asbestos-related liabilities in connection with a prior asset 563  
purchase, stock purchase, merger, or consolidation involving a 564  
prior transferor, the assets of the successor described in 565  
division (C)(1) of this section shall be exempt from restraint, 566  
attachment, or execution on any judgment entered in this state or 567  
another jurisdiction related to any claim for successor 568

asbestos-related liabilities if the cumulative amounts of those 569  
liabilities that, after the effective date of the prior asset 570  
purchase, stock purchase, merger, or consolidation, are paid or 571  
committed to be paid by or on behalf of the successor, or by or on 572  
behalf of the prior transferor, in connection with any judgment, 573  
settlement, or other discharge of claims of asbestos-related 574  
liabilities, exceed the fair market value of the previously 575  
acquired assets or stock as determined on the effective date of 576  
the prior asset purchase, stock purchase, merger, or 577  
consolidation. 578

(D)(1) A successor may establish the fair market value of 579  
total assets under division (B) or (C) of this section by means of 580  
any method that is reasonable under the circumstances, including 581  
by reference to the going-concern value of those assets, to the 582  
purchase price attributable to or paid for the assets in an arm's 583  
length transaction, or, in the absence of other readily available 584  
information from which fair market value can be determined, to the 585  
value of those assets recorded on a balance sheet. Total assets 586  
shall include intangible assets. A showing by the successor of a 587  
reasonable determination of the fair market value of total assets 588  
is prima-facie evidence of the fair market value of those assets. 589

(2) After a successor has established a reasonable 590  
determination of the fair market value of total assets under 591  
division (D)(1) of this section, a claimant that disputes that 592  
determination of the fair market value has the burden of 593  
establishing a different fair market value of those assets. 594

(3) For the purpose of adjusting the limitations set forth in 595  
division (B) or (C) of this section to account for the passage of 596  
time, the fair market value of total assets on the effective date 597  
of the applicable asset purchase or stock purchase under the 598  
applicable division shall be increased annually, at the rate equal 599  
to the prime rate as listed in the first edition of the Wall 600

Street Journal published for each calendar year since the asset 601  
purchase or stock purchase plus one per cent, not compounded, 602  
until the earlier of either of the following: 603

(a) The date of the judgment, settlement, or other discharge 604  
of claims of successor asbestos-related liabilities to which the 605  
limitations in division (B) or (C) of this section are being 606  
applied; 607

(b) The date on which the adjusted fair market value of total 608  
assets under division (D)(3) of this section is first exceeded by 609  
the cumulative amounts of successor asbestos-related liabilities 610  
that are paid or committed to be paid by or on behalf of the 611  
successor, or by or on behalf of a transferor, after the effective 612  
date of the asset purchase or stock purchase in connection with 613  
any judgment, settlement, or other discharge of the successor 614  
asbestos-related liabilities. 615

(E)(1) The limitations set forth in divisions (B) and (C) of 616  
this section shall apply to the following: 617

(a) All asbestos claims, including asbestos claims that are 618  
pending on the effective date of this section, and all litigation 619  
involving asbestos claims, including litigation that is pending on 620  
the effective date of this section; 621

(b) Successors of a successor to which this section applies. 622

(2) The limitations set forth in divisions (B) and (C) of 623  
this section do not apply to any of the following: 624

(a) Workers' compensation benefits that are paid by or on 625  
behalf of an employer to an employee pursuant to any provision of 626  
Chapter 4121., 4123., 4127., or 4131. of the Revised Code or 627  
comparable workers' compensation law of another jurisdiction; 628

(b) Any claim against a successor that does not constitute a 629  
claim for a successor asbestos-related liability; 630

(c) An insurance corporation; 631

(d) Any obligations arising under the "National Labor 632  
Relations Act," 49 Stat. 449, 29 U.S.C. 151 et seq., as amended, 633  
or under any collective bargaining agreement. 634

**Sec. 2307.97.** (A) A holder of shares, an owner of any 635  
beneficial interest in shares, or a subscriber for shares whose 636  
subscription has been accepted, or any affiliate or holding 637  
company of that holder, owner, or subscriber or of the 638  
corporation, shall be under no obligation to, and shall have no 639  
liability to, the corporation or to any person with respect to any 640  
obligation or liability of the corporation relating in any way to 641  
asbestos claims on the basis that the holder, owner, subscriber, 642  
affiliate, or holding company described in division (A) of this 643  
section controlled the corporation or is or was the alter ego of 644  
the corporation, or on the basis of actual fraud or constructive 645  
fraud, a sham to perpetrate a fraud, a fraudulent conveyance, 646  
piercing the corporate veil, or any other similar theory, unless 647  
the person demonstrates that the holder, owner, subscriber, 648  
affiliate, or holding company caused the corporation to be used 649  
for the purpose of perpetrating and did perpetrate an actual fraud 650  
on the person primarily for the direct pecuniary benefit of the 651  
holder, owner, subscriber, affiliate, or holding company, and then 652  
only to the extent of that direct pecuniary benefit. 653

(B) Any liability of the holder, owner, or subscriber of 654  
shares of a corporation described in division (A) of this section 655  
or any affiliate or holding company of that holder, owner, or 656  
subscriber or of the corporation for an obligation or liability 657  
that is limited by that division is exclusive and preempts any 658  
other obligation or liability imposed upon a holder, owner, or 659  
subscriber of shares of a corporation described in that division 660  
or any affiliate or holding company of that holder, owner, or 661

subscriber or of the corporation for that obligation or liability 662  
under common law or otherwise. 663

**Section 2.** That existing sections 1701.76 and 1701.82 of the 664  
Revised Code are hereby repealed. 665

**Section 3.** (A) The General Assembly makes the following 666  
statement of findings and intent: 667

(1) Asbestos claims have created an increased amount of 668  
litigation in state and federal courts that the United States 669  
Supreme Court has characterized as "an elephant mass" of cases 670  
that "defies customary judicial administration and calls for 671  
national legislation." *Ortiz v. Fibreboard Corporation* (1999), 119 672  
S.Ct. 2295, 2303. 673

(2) The current asbestos personal injury litigation system is 674  
unfair and inefficient, imposing a severe burden on litigants and 675  
taxpayers alike. 676

(3) The extraordinary volume of nonmalignant asbestos cases 677  
continue to strain federal and state courts, with over two hundred 678  
thousand cases pending and over fifty thousand new cases filed 679  
each year. 680

(4) Asbestos personal injury litigation has already 681  
contributed to the bankruptcy of more than sixty companies, 682  
including nearly all manufacturers of asbestos textile and 683  
insulation products, and the ratio of asbestos-driven bankruptcies 684  
is accelerating. 685

(5) The General Assembly recognizes that the vast majority of 686  
asbestos claims are filed by individuals who allege they have been 687  
exposed to asbestos and who have some physical sign of exposure to 688  
asbestos, but who do not suffer from an asbestos-related 689  
impairment. 690

(6) The cost of compensating exposed individuals who are not ill jeopardizes the ability of defendants to compensate people with cancer and other serious asbestos-related diseases, now and in the future; threatens savings, retirement benefits, and jobs of the state's current and retired employees; adversely affects the communities in which these defendants operate; and impairs Ohio's economy.

(7) As stated in testimony by Robert Bunda, a trial lawyer who has been involved with the defense of asbestos claims on behalf of Owens-Illinois, Inc. for twenty-four years, there is something terribly wrong with the current civil justice system, evidenced by the fact that Owens-Illinois has been sued over three hundred thousand times for its brief involvement in manufacturing asbestos. According to Mr. Bunda, at least five Ohio-based companies have gone bankrupt because of the cost of paying people who are not sick. These bankruptcies have imperiled the availability of even modest compensation for the most seriously injured asbestos workers. They have also imperiled jobs, the health benefits, and the retirement funds of tens of thousands of blue-collar workers. New jobs are not being created in Ohio, and existing Ohio jobs are being destroyed.

(8) According to a study conducted by NERA Economic Consulting, in 2000, Owens-Corning laid off two hundred and seventy-five employees from its Granville, Ohio plant. The ripple effect of those job losses predicts total employment in the county of almost five hundred jobs and a fifteen million to twenty million dollar annual reduction in regional income.

(9) The public interest requires the deferring of claims of exposed individuals who are not ill in order to preserve, now and for the future, defendants' ability to compensate people who develop cancer and other serious asbestos-related injuries and to safeguard the jobs, benefits, and savings of the state's employees

and the well being of the Ohio economy. 723

(B) In enacting sections 2307.91 to 2307.97 of the Revised 724  
Code, it is the intent of the General Assembly to: (1) give 725  
priority to those asbestos claimants who can demonstrate actual 726  
physical harm or illness caused by exposure to asbestos; (2) fully 727  
preserve the rights of claimants who were exposed to asbestos to 728  
pursue compensation should those claimants become impaired in the 729  
future as a result of such exposure; (3) enhance the ability of 730  
the state's judicial systems and federal judicial systems to 731  
supervise and control litigation and asbestos-related bankruptcy 732  
proceedings; and (4) conserve the scarce resources of the 733  
defendants to allow compensation of cancer victims and others who 734  
are physically impaired by exposure to asbestos while securing the 735  
right to similar compensation for those who may suffer physical 736  
impairment in the future. 737

**Section 4.** (A) As used in this section, "asbestos," "asbestos 738  
claim," "exposed person," and "substantial contributing factor" 739  
have the same meanings as in section 2307.91 of the Revised Code. 740

(B) The General Assembly acknowledges the Court's authority 741  
in prescribing rules governing practice and procedure in the 742  
courts of this state, as provided by Section 5 of Article IV of 743  
the Ohio Constitution. 744

(C) The General Assembly hereby requests the Supreme Court to 745  
adopt rules to specify procedures for venue and consolidation of 746  
asbestos claims brought pursuant to sections 2307.91 to 2307.95 of 747  
the Revised Code. 748

(D) With respect procedures for venue in regard to asbestos 749  
claims, the General Assembly hereby requests the Supreme Court to 750  
adopt a rule that requires that an asbestos claim meet specific 751  
nexus requirements, including the requirement that the plaintiff 752

be domiciled in Ohio or that Ohio is the state in which the 753  
plaintiff's exposure to asbestos is a substantial contributing 754  
factor. 755

(E) With respect to procedures for consolidation of asbestos 756  
claims, the General Assembly hereby requests the Supreme Court to 757  
adopt a rule that permits consolidation of asbestos claims only 758  
with the consent of all parties, and in absence of that consent, 759  
permits a court to consolidate for trial only those asbestos 760  
claims that relate to the same exposed person and members of the 761  
exposed person's household. 762

**Section 5.** If any item of law that constitutes the whole or 763  
part of a section of law contained in this act, or if any 764  
application of any item of law that constitutes the whole or part 765  
of a section of law contained in this act, is held invalid, the 766  
invalidity does not affect other items of law or applications of 767  
items of law that can be given effect without the invalid item of 768  
law or application. To this end, the items of law of which the 769  
sections contained in this act are composed, and their 770  
applications, are independent and severable. 771

**Section 6.** If any item of law that constitutes the whole or 772  
part of a section of law contained in this act, or if any 773  
application of any item of law contained in this act, is held to 774  
be preempted by federal law, the preemption of the item of law or 775  
its application does not affect other items of law or applications 776  
that can be given affect. The items of law of which the sections 777  
of this act are composed, and their applications, are independent 778  
and severable. 779